Nektar Therapeutics Income from Continuous Operations 2010-2024 | NKTR

Nektar Therapeutics income from continuous operations from 2010 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
Nektar Therapeutics Annual Income from Continuous Operations
(Millions of US $)
2023 $-276
2022 $-368
2021 $-524
2020 $-444
2019 $-441
2018 $681
2017 $-97
2016 $-154
2015 $-81
2014 $-54
2013 $-162
2012 $-172
2011 $-134
2010 $-38
2009 $-103
Nektar Therapeutics Quarterly Income from Continuous Operations
(Millions of US $)
2024-06-30 $-52
2024-03-31 $-37
2023-12-31 $-42
2023-09-30 $-46
2023-06-30 $-51
2023-03-31 $-137
2022-12-31 $-60
2022-09-30 $-59
2022-06-30 $-159
2022-03-31 $-90
2021-12-31 $-146
2021-09-30 $-130
2021-06-30 $-126
2021-03-31 $-123
2020-12-31 $-117
2020-09-30 $-109
2020-06-30 $-80
2020-03-31 $-139
2019-12-31 $-112
2019-09-30 $-99
2019-06-30 $-110
2019-03-31 $-120
2018-12-31 $-98
2018-09-30 $-96
2018-06-30 $971
2018-03-31 $-96
2017-12-31 $-34
2017-09-30 $61
2017-06-30 $-60
2017-03-31 $-64
2016-12-31 $-42
2016-09-30 $-43
2016-06-30 $-49
2016-03-31 $-19
2015-12-31 $-54
2015-09-30 $-8
2015-06-30 $-53
2015-03-31 $34
2014-12-31 $-46
2014-09-30 $71
2014-06-30 $-33
2014-03-31 $-46
2013-12-31 $-48
2013-09-30 $-17
2013-06-30 $-43
2013-03-31 $-55
2012-12-31 $-53
2012-09-30 $-44
2012-06-30 $-34
2012-03-31 $-41
2011-12-31 $-37
2011-09-30 $-24
2011-06-30 $-36
2011-03-31 $-36
2010-12-31 $-23
2010-09-30 $-9
2010-06-30 $-1
2010-03-31 $-6
2009-12-31 $-8
2009-09-30 $-31
2009-06-30 $-32
2009-03-31 $-32
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.258B $0.090B
Nektar Therapeutics is a biopharmaceutical company, focused on the development of treatments utilizing its PEGylation and advanced polymer conjugate technology platforms. Nektar primarily finances its operations with funds from licensing, collaboration and manufacturing agreements. It has collaboration deals with companies namely AstraZeneca, Pfizer, Roche, Amgen, Bristol-Myers and Eli Lilly among others. The company's most lucrative deal is with Bristol-Myers, which provided the company with significant cash resources to support progress of its pipeline and share development costs for its lead candidate, bempegaldesleukin. Nektar recognizes product sales from its manufacturing and supply agreements with several pharma companies related to products developed using its PEGylation platform. The company also earns royalty payments from the sales of products using its technology platforms. Amgen's neutropenia drug, Neulasta is one of the drugs developed using Nektar's PEGylation platform.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $79.775B 30.70
Takeda Pharmaceutical (TAK) Japan $43.846B 9.13
Merck (MKKGY) Germany $21.021B 22.94
Astellas Pharma (ALPMY) Japan $20.214B 18.62
Sandoz Group AG (SDZNY) Switzerland $19.826B 0.00
United Therapeutics (UTHR) United States $18.304B 18.01
Summit Therapeutics (SMMT) United States $15.789B 0.00
Neurocrine Biosciences (NBIX) United States $12.731B 33.71
Shionogi (SGIOY) Japan $12.473B 11.95
Catalent (CTLT) United States $10.784B 0.00
Madrigal Pharmaceuticals (MDGL) United States $7.649B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $7.633B 7.31
Orion OYJ (ORINY) Finland $6.848B 19.25
Corcept Therapeutics (CORT) United States $6.245B 47.30
Ionis Pharmaceuticals (IONS) United States $6.188B 0.00
Crinetics Pharmaceuticals (CRNX) United States $4.857B 0.00
PTC Therapeutics (PTCT) United States $3.406B 0.00
Dyne Therapeutics (DYN) United States $2.859B 0.00
Catalyst Pharmaceuticals (CPRX) United States $2.854B 12.94
Arrowhead Pharmaceuticals (ARWR) United States $2.721B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.702B 16.17
Soleno Therapeutics (SLNO) United States $2.460B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $2.171B 0.00
Recursion Pharmaceuticals (RXRX) United States $1.996B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $1.870B 0.00
Harrow (HROW) United States $1.863B 0.00
Ocular Therapeutix (OCUL) United States $1.731B 0.00
Xencor (XNCR) United States $1.653B 0.00
ARS Pharmaceuticals (SPRY) United States $1.652B 0.00
BioCryst Pharmaceuticals (BCRX) United States $1.611B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $1.535B 0.00
Evotec AG (EVO) Germany $1.464B 0.00
Indivior (INDV) United States $1.413B 5.76
Enliven Therapeutics (ELVN) United States $1.368B 0.00
Guardian Pharmacy Services (GRDN) United States $1.329B 0.00
Cassava Sciences (SAVA) United States $1.293B 0.00
Ardelyx (ARDX) United States $1.201B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.190B 0.00
Collegium Pharmaceutical (COLL) United States $1.036B 5.66
Bioventus (BVS) United States $0.957B 30.31
Relay Therapeutics (RLAY) United States $0.830B 0.00
Ironwood Pharmaceuticals (IRWD) United States $0.792B 0.00
USANA Health Sciences (USNA) United States $0.767B 14.22
Cronos Group (CRON) Canada $0.765B 0.00
Tourmaline Bio (TRML) United States $0.737B 0.00
Exscientia (EXAI) United Kingdom $0.658B 0.00
Korro Bio (KRRO) United States $0.655B 0.00
Savara (SVRA) United States $0.653B 0.00
ProKidney (PROK) United States $0.579B 0.00
Larimar Therapeutics (LRMR) United States $0.569B 0.00
Altimmune (ALT) United States $0.546B 0.00
Elite Pharmaceuticals (ELTP) United States $0.545B 50.98
Siga Technologies (SIGA) United States $0.540B 6.31
Verve Therapeutics (VERV) United States $0.534B 0.00
OmniAb (OABI) United States $0.534B 0.00
Silence Therapeutics (SLN) United Kingdom $0.524B 0.00
Xeris Biopharma Holdings (XERS) United States $0.517B 0.00
Aquestive Therapeutics (AQST) United States $0.498B 0.00
KalVista Pharmaceuticals (KALV) United States $0.493B 0.00
Zevra Therapeutics (ZVRA) United States $0.474B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.456B 0.00
Esperion Therapeutics (ESPR) United States $0.447B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.437B 0.00
Organogenesis (ORGO) United States $0.435B 0.00
4D Molecular Therapeutics (FDMT) United States $0.422B 0.00
Akebia Therapeutics (AKBA) United States $0.408B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.388B 157.64
Sage Therapeutics (SAGE) United States $0.386B 0.00
Aldeyra Therapeutics (ALDX) United States $0.328B 0.00
Lyell Immunopharma (LYEL) United States $0.312B 0.00
Avita Medical (RCEL) United States $0.311B 0.00
Nature's Sunshine Products (NATR) United States $0.276B 16.37
Acrivon Therapeutics (ACRV) United States $0.265B 0.00
Heron Therapeutics (HRTX) United States $0.265B 0.00
Lexeo Therapeutics (LXEO) United States $0.264B 0.00
Pyxis Oncology (PYXS) United States $0.263B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.235B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.226B 0.00
Profound Medical (PROF) Canada $0.216B 0.00
Nanobiotix S.A (NBTX) France $0.198B 0.00
Aclaris Therapeutics (ACRS) United States $0.189B 0.00
Galectin Therapeutics (GALT) United States $0.187B 0.00
MediWound (MDWD) Israel $0.186B 0.00
Innate Pharma SA (IPHYF) France $0.180B 0.00
Incannex Healthcare (IXHL) Australia $0.176B 0.00
Achieve Life Sciences (ACHV) Canada $0.159B 0.00
Cardiol Therapeutics (CRDL) Canada $0.159B 0.00
CytoDyn (CYDY) United States $0.150B 0.00
Context Therapeutics (CNTX) United States $0.146B 0.00
Telomir Pharmaceuticals (TELO) United States $0.125B 0.00
Century Therapeutics (IPSC) United States $0.122B 0.00
VAXART, INC (VXRT) United States $0.122B 0.00
Fractyl Health (GUTS) United States $0.118B 0.00
OptiNose (OPTN) United States $0.118B 0.00
Journey Medical (DERM) United States $0.117B 0.00
Karyopharm Therapeutics (KPTI) United States $0.110B 0.00
Relmada Therapeutics (RLMD) United States $0.099B 0.00
Regulus Therapeutics (RGLS) United States $0.096B 0.00
Arch Biopartners (ACHFF) Canada $0.094B 0.00
PMV Pharmaceuticals (PMVP) United States $0.090B 0.00
ElectroCore (ECOR) United States $0.087B 0.00
CASI Pharmaceuticals (CASI) China $0.085B 0.00
Assertio Holdings (ASRT) United States $0.081B 14.17
ESSA Pharma (EPIX) Canada $0.080B 0.00
Inotiv (NOTV) United States $0.078B 0.00
Swiftmerge Acquisition (IVCP) United States $0.076B 368.67
Metagenomi (MGX) United States $0.076B 0.00
Citius Pharmaceuticals (CTXR) United States $0.074B 0.00
AlloVir (ALVR) United States $0.071B 0.00
Vivani Medical (VANI) United States $0.070B 0.00
Prelude Therapeutics (PRLD) United States $0.065B 0.00
Champions Oncology (CSBR) United States $0.061B 0.00
Mural Oncology (MURA) Ireland $0.060B 0.00
Nutriband (NTRB) United States $0.059B 0.00
Gain Therapeutics (GANX) United States $0.057B 0.00
Unicycive Therapeutics (UNCY) United States $0.056B 0.00
BGM Group (BGM) China $0.053B 0.00
Protara Therapeutics (TARA) United States $0.052B 0.00
SCYNEXIS (SCYX) United States $0.050B 0.00
Rafael Holdings (RFL) United States $0.048B 0.00
VYNE Therapeutics (VYNE) United States $0.047B 0.00
Carisma Therapeutics (CARM) United States $0.042B 0.00
DURECT (DRRX) United States $0.041B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.038B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.037B 0.00
BioLineRx (BLRX) Israel $0.036B 0.00
Surrozen (SRZN) United States $0.033B 0.00
FibroGen (FGEN) United States $0.032B 0.00
Oruka Therapeutics (ORKA) United States $0.032B 0.00
Iterum Therapeutics (ITRM) Ireland $0.032B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.031B 0.00
Natural Alternatives (NAII) United States $0.028B 0.00
Tempest Therapeutics (TPST) United States $0.027B 0.00
GlycoMimetics (GLYC) United States $0.027B 0.00
Enlivex Therapeutics (ENLV) Israel $0.026B 0.00
BioVie (BIVI) United States $0.026B 0.00
Lipocine (LPCN) United States $0.025B 0.00
Inhibikase Therapeutics (IKT) United States $0.022B 0.00
MEI Pharma (MEIP) United States $0.020B 0.71
Tonix Pharmaceuticals Holding (TNXP) United States $0.019B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.019B 0.00
TherapeuticsMD (TXMD) United States $0.018B 0.00
Lyra Therapeutics (LYRA) United States $0.018B 0.00
PolyPid (PYPD) Israel $0.017B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.017B 0.00
Minerva Neurosciences (NERV) United States $0.016B 0.00
Cosmos Health (COSM) United States $0.016B 0.00
Talphera (TLPH) United States $0.015B 0.00
Mannatech (MTEX) United States $0.015B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.015B 0.00
ProPhase Labs (PRPH) United States $0.015B 0.00
Vivos Therapeutics (VVOS) United States $0.015B 0.00
NRx Pharmaceuticals (NRXP) United States $0.014B 0.00
Scienture Holdings (SCNX) United States $0.014B 0.00
Nuvilex (PMCB) United States $0.014B 0.00
Avalo Therapeutics (AVTX) United States $0.014B 0.00
Indaptus Therapeutics (INDP) United States $0.012B 0.00
Addex Therapeutics (ADXN) Switzerland $0.011B 0.00
CERo Therapeutics Holdings (CERO) United States $0.011B 0.00
Dominari Holdings (DOMH) United States $0.010B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.010B 0.00
Conduit Pharmaceuticals (CDT) United States $0.010B 0.00
Redhill Biopharma (RDHL) Israel $0.010B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.010B 0.00
Traws Pharma (TRAW) United States $0.010B 0.00
Jaguar Animal Health (JAGX) United States $0.009B 0.00
TransCode Therapeutics (RNAZ) United States $0.008B 0.00
Plus Therapeutics (PSTV) United States $0.007B 0.00
Viracta Therapeutics (VIRX) United States $0.007B 0.00
Biomerica (BMRA) United States $0.007B 0.00
Aptorum Group (APM) United Kingdom $0.006B 0.00
Klotho Neurosciences (KLTO) United States $0.006B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
Mangoceuticals (MGRX) United States $0.005B 0.00
Ainos (AIMD) United States $0.004B 0.00
SHINECO (SISI) China $0.004B 0.00
Oncternal Therapeutics (ONCT) United States $0.004B 0.00
TNF Pharmaceuticals (TNFA) United States $0.004B 0.00
Heatwurx (PCSA) United States $0.004B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.003B 0.00
Petros Pharmaceuticals (PTPI) United States $0.003B 0.00
Alaunos Therapeutics (TCRT) United States $0.003B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
Avenue Therapeutics (ATXI) United States $0.003B 0.09
XORTX Therapeutics (XRTX) Canada $0.003B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.003B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.003B 0.00
Clearmind Medicine (CMND) Canada $0.003B 0.00
Phio Pharmaceuticals (PHIO) United States $0.003B 0.00
SciSparc (SPRC) Israel $0.002B 0.00
Molecular Templates (MTEM) United States $0.002B 0.00
Bio-Path Holdings (BPTH) United States $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
China SXT Pharmaceuticals (SXTC) China $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.002B 0.00
Altamira Therapeutics (CYTO) Bermuda $0.002B 0.00
Aditxt (ADTX) United States $0.002B 0.00
Qualigen Therapeutics (QLGN) United States $0.001B 0.00
Universe Pharmaceuticals INC (UPC) China $0.001B 0.00
PainReform (PRFX) Israel $0.000B 0.00
Grifols, S.A (GRFS) Spain $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Procaps Group, S.A (PROC) Luxembourg $0.000B 2.98
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Stevanato Group S.p.A (STVN) Italy $0.000B 42.71